Adult Vaccines Market Is Forecasted To Witness A Thriving Growth By 2026 Adult Vaccines Market - by Vaccine (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), by Vaccine Type (Monovalent and Multivalent), by Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines), and by Region - Global Industry Insights, and Forecast till 2025 The Global Adult Vaccines Market was valued at US$ 12,806.49 million in 2017 and is expected to witness a robust CAGR of 7.1% over the forecast period (2017 - 2025). Vaccination and immunization is aids in prevention of diseases among adults and children. Vaccines are biological suspensions that contain an agent that resembles the disease causing microorganisms and are often made from inactivated microbes, toxins or surface proteins. The active agents present in the vaccine stimulates body’s immune system to recognize the disease causing agent as 'foreign substance' and develop antibodies against it. Vaccines are a preferable and highly recommended preventive measure against certain severe diseases, however, have mild side effects. Market Dynamics Development of vaccines for various new diseases and rising awareness regarding advantages of preventive medication are the two prominent factors supporting growth of the market. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden. Among the middle-income and emerging economies, relevant Indian government funding agencies such as Department of Biotechnology (DBT) and The Indian Council of Medical Research (ICMR) are scaling up their investments in research and development associated to vaccine development. For instance, in 2015, the Department of Biotechnology projected a funding of US$ 2.95 million for Malaria Vaccine Initiative, to develop vaccine against Plasmodium falciparum and P. vivax. On the other hand, growing awareness among the populace regarding prevention of diseases facilitated by vaccines is expected to augment the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden. Moreover, according to a study from the Society for Risk Analysis, 2016, GDP loss of a pandemic outbreak in the U.S. was recorded between US$ 34.4 billion and US$ 45.3 billion. However, a large population not being vaccinated poses as a restraint for growth of the market. Among region, the market in North America held a dominant position in the global adult vaccines market in 2016. This is attributed to increasing investments facilitated by government as well as the manufacturers consistently focusing on promoting immunization in the U.S. For instance, in 2015, The Centers for Medicare & Medicaid Services (CMS), in alignment with the Centers for Disease Control and Prevention (CDC) introduced a five-year initiative named Healthy People 2020, to improve adult immunization as well as reduce the disparity rates caused majorly due to pneumonia, shingles, and influenza by working directly with physicians and provider offices, as well as with home health agencies, hospitals, beneficiaries and others under the guidance of Health Service Advisory Group (HSAG). Moreover, favorable Medicare coverage for adult vaccination in the U.S. also poses as a key factor favoring growth of the adult vaccines market. Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1091 Key players operating in the global adult vaccines market include GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer, Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc. Market players are engaged in development vaccines to cater to diseases with high epidemic Market players are increasingly focusing on developing vaccines that caters to diseases with highest probability of causing an epidemic. For instance, in February 2017, an India-based drug firm, Cipla, in collaboration with Serum Institute of India, introduced Hepatitis B vaccine for adults in the country. The disease affects chronically over 40 million people in the country, as per India’s Universal Immunization Programme. Moreover, Dynavax Technologies Corporation received FDA approval in 2018, for its two-dosed Hepatitis-B vaccine indicated for adults aged 18 years and older. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: [email protected]

The Global Adult Vaccines Market was valued at US$ 12,806.49 million in 2017 and is expected to witness a robust CAGR of 7.1% over the forecast period (2017 - 2025). Vaccination and immunization is aids in prevention of diseases among adults and children. Vaccines are biological suspensions that contain an agent that resembles the disease causing microorganisms and are often made from inactivated microbes, toxins or surface proteins.